Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Cellular interactions of farnesol, a quorum-sensing molecule produced by Candida albicans.

Langford ML, Atkin AL, Nickerson KW.

Future Microbiol. 2009 Dec;4(10):1353-62. doi: 10.2217/fmb.09.98. Review.

PMID:
19995193
2.

Farnesol-induced apoptosis in Candida albicans.

Shirtliff ME, Krom BP, Meijering RA, Peters BM, Zhu J, Scheper MA, Harris ML, Jabra-Rizk MA.

Antimicrob Agents Chemother. 2009 Jun;53(6):2392-401. doi: 10.1128/AAC.01551-08. Epub 2009 Apr 13.

3.

Pseudomonas aeruginosa-Candida albicans interactions: localization and fungal toxicity of a phenazine derivative.

Gibson J, Sood A, Hogan DA.

Appl Environ Microbiol. 2009 Jan;75(2):504-13. doi: 10.1128/AEM.01037-08. Epub 2008 Nov 14.

4.

Protective effects of farnesol against oral candidiasis in mice.

Hisajima T, Maruyama N, Tanabe Y, Ishibashi H, Yamada T, Makimura K, Nishiyama Y, Funakoshi K, Oshima H, Abe S.

Microbiol Immunol. 2008 Jul;52(7):327-33. doi: 10.1111/j.1348-0421.2008.00044.x.

5.

Candida albicans Tup1 is involved in farnesol-mediated inhibition of filamentous-growth induction.

Kebaara BW, Langford ML, Navarathna DH, Dumitru R, Nickerson KW, Atkin AL.

Eukaryot Cell. 2008 Jun;7(6):980-7. doi: 10.1128/EC.00357-07. Epub 2008 Apr 18.

6.

Farnesol and dodecanol effects on the Candida albicans Ras1-cAMP signalling pathway and the regulation of morphogenesis.

Davis-Hanna A, Piispanen AE, Stateva LI, Hogan DA.

Mol Microbiol. 2008 Jan;67(1):47-62.

7.
8.

Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans.

Navarathna DH, Hornby JM, Krishnan N, Parkhurst A, Duhamel GE, Nickerson KW.

Infect Immun. 2007 Apr;75(4):1609-18. Epub 2007 Feb 5.

9.

In vivo and in vitro anaerobic mating in Candida albicans.

Dumitru R, Navarathna DH, Semighini CP, Elowsky CG, Dumitru RV, Dignard D, Whiteway M, Atkin AL, Nickerson KW.

Eukaryot Cell. 2007 Mar;6(3):465-72. Epub 2007 Jan 26.

10.

Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance.

Jabra-Rizk MA, Shirtliff M, James C, Meiller T.

FEMS Yeast Res. 2006 Nov;6(7):1063-73.

11.

Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis.

Navarathna DH, Hornby JM, Hoerrmann N, Parkhurst AM, Duhamel GE, Nickerson KW.

J Antimicrob Chemother. 2005 Dec;56(6):1156-9. Epub 2005 Oct 20.

PMID:
16239285
12.

Farnesol concentrations required to block germ tube formation in Candida albicans in the presence and absence of serum.

Mosel DD, Dumitru R, Hornby JM, Atkin AL, Nickerson KW.

Appl Environ Microbiol. 2005 Aug;71(8):4938-40.

13.

Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs.

Dumitru R, Hornby JM, Nickerson KW.

Antimicrob Agents Chemother. 2004 Jul;48(7):2350-4.

14.

Membrane-derived oligosaccharides (MDOs) are essential for sodium dodecyl sulfate resistance in Escherichia coli.

Rajagopal S, Eis N, Bhattacharya M, Nickerson KW.

FEMS Microbiol Lett. 2003 Jun 6;223(1):25-31.

15.

Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule.

Ramage G, Saville SP, Wickes BL, López-Ribot JL.

Appl Environ Microbiol. 2002 Nov;68(11):5459-63.

16.

Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol.

Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, Shoemaker R, Dussault P, Nickerson KW.

Appl Environ Microbiol. 2001 Jul;67(7):2982-92.

17.

Supplemental Content

Support Center